Company news

Acrux Limited news in 2024

Acrux Limited's news releases, calls and decks from 2024, newest first.

View company

Acrux raises $1.34 million from SPP

December 22, 2024

Investor Deck update, SPP Closes 18 December 2024, 5pm

December 17, 2024

Commercialisation of Nitroglycerin Ointment

December 12, 2024

Share Purchase Plan Offer Booklet

December 5, 2024

Investor Presentation

December 5, 2024

Share Placement successfully concluded and SPP launched

December 4, 2024

FDA Approval - Nitroglycerin Ointment

December 3, 2024

Trading Halt

December 2, 2024

AGM Presentation

November 20, 2024

FY24 R&D Tax Incentive rebate received

October 1, 2024

ASX Small and Mid Cap Conference presentation

September 23, 2024

FY24 Full Year Results - Investor Presentation

August 29, 2024

Appendix 4E and FY24 Full Year Statutory Accounts

August 29, 2024

FDA Approval received for Dapsone Gel, 7.5%

August 26, 2024

Quarterly Activities Report and Appendix 4C - June 2024

July 25, 2024

Acrux presentation to Bioshares, 18th Biotech Summit

July 14, 2024

RDTI funding facility secured

June 27, 2024

Acrux presentation at Hidden Gems in Lifesciences Forum

June 12, 2024

Launch of Dapsone 5%, Gel in the United States

April 2, 2024

Investor Presentation Half Year Accounts

February 27, 2024

Appendix 4D and Half Year Accounts

February 27, 2024

Appendix 4C and Activities Statement

January 30, 2024

Decks in 2024